[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338423-105":59,"doc-detail-338423-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancing-immunotherapy-in-pancreatic-cancer","Advancing Immunotherapy in Pancreatic Cancer","","Pancreatic cancer remains among the deadliest malignancies, characterized by persistently low five-year survival despite decades of therapeutic progress. Improvements in outcomes have been modest, largely driven by incremental cytotoxic chemotherapy advances, while other treatment strategies lag behind. Immunomodulatory therapies are now a major research focus, spanning antibody-based approaches, cellular therapies, and vaccines. Despite mixed early results, recent clinical trials report meaningful patient benefits. This review compares the three approaches by shared targets and distinct limitations, and summarizes completed and ongoing trials to guide future investigation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancing-immunotherapy-in-pancreatic-cancer/338423/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancing-immunotherapy-in-pancreatic-cancer/338423.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is pancreatic cancer prognosis generally poor compared with other cancers?","Question",{"text":112,"@type":113},"Pancreatic ductal adenocarcinoma is frequently diagnosed at late, unresectable or metastatic stages, leading to very low five-year survival. Even with advances in other solid tumors, PDAC outcomes have remained dismally poor.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the main immunomodulatory therapy approaches reviewed for pancreatic cancer?",{"text":117,"@type":113},"The review details three immunomodulation strategies: antibody-based approaches, cellular therapies, and vaccines, comparing their common targets and different shortcomings.",{"name":119,"@type":110,"acceptedAnswer":120},"How do immune checkpoint inhibitors work in PDAC treatment, and what limitation is highlighted?",{"text":121,"@type":113},"Checkpoint pathways such as PD-1/PD-L1 prevent T-cell activation; blocking them enables immune recognition and tumor attack. Their use as second-line therapy is limited mainly to mismatch repair deficient (dMMR) tumors due to stronger responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338423,1790520424,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review  \nAdvancing Immunotherapy in Pancreatic Cancer  \nAhmad Hegazi †, Lauren Elizabeth Rager †, Dean Edward Watkins  and Kuo-Hui Su *  \nCitation: Hegazi, A.; Rager, L.E.; Watkins, D.E.; Su, K.-H. Advancing Immunotherapy in Pancreatic Cancer. Int. J. Mol. Sci. 2024, 25, 11560 . [https://doi.org/10.3390/ijms252111560](https://doi.org/10.3390/ijms252111560)  \nAcademic Editors: Akira Sato and Tetsufumi Takahashi  \nReceived: 8 October 2024  \nRevised: 21 October 2024  \nAccepted: 22 October 2024  \nPublished: 28 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Cell and Cancer Biology, College of Medicine and Life Sciences, The University of Toledo,  \nToledo, OH 43614, USA; [ahmad.hegazi@rockets.utoledo.edu](ahmad.hegazi@rockets.utoledo.edu) (A.H.); [lauren.rager@rockets.utoledo.edu](lauren.rager@rockets.utoledo.edu) (L.E.R.);  \n[dean.watkins@rockets.utoledo.edu](dean.watkins@rockets.utoledo.edu) (D.E.W.)  \n* Correspondence: [kuo-hui.su@utoledo.edu](kuo-hui.su@utoledo.edu); Tel.: +1-419-383-4527 † These authors contributed equally to this work.  \nAbstract: Pancreatic cancer remains one of the deadliest malignancies, with a consistently low fiveyear survival rate for the past several decades. This is in stark contrast to other cancers, which have seen significant improvement in survival and prognosis due to recent developments in therapeutic modalities. These modest improvements in pancreatic cancer outcomes have primarily resulted from minor advances in cytotoxic chemotherapeutics, with limited progress in other treatment approaches. A major focus of current therapeutic research is the further development of immunomodulatory therapies characterized by antibody-based approaches, cellular therapies, and vaccines. Although initial results utilizing immunotherapy in pancreatic cancer have been mixed, recent clinical trials have demonstrated significant improvements in patient outcomes. In this review, we detail these three approaches to immunomodulation, highlighting their common targets and distinct shortcomings, and we provide a narrative summary of completed and ongoing clinical trials that utilize these approaches to immunomodulation. Within this context, we aim to inform future research efforts by identifying promising areas that warrant further exploration.  \nKeywords: immunotherapy; pancreatic cancer; antibody therapy; vaccine therapy; cellular therapy; clinical trial; immune checkpoint inhibitor  \n1. Introduction  \nPancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related deaths in the United States and the third-leading cause of cancer-related deaths between the ages of 50 and 79 years [1] . Approximately 85% of patients were found to have late-stage unresectable or metastatic disease at diagnosis, resulting in a five-year survival rate of 13%, among the lowest of all cancers [1,2] . Despite rapid advances in the treatment of other solid tumor types with innovative immunotherapies, the prognosis of PDAC has remained dismally poor, with only resectable tumors having curative treatment options in the case of surgery. Currently, the first-line treatment across all pancreatic cancer patients is either a combination regimen with 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) or liposomal irinotecan (NALIRIFOX), or gemcitabine combined with nabpaclitaxel (GnP) [3,4] . Unfortunately, these modalities are often accompanied by significant toxicities or rendered ineffective by innate or acquired tumor resistance [4] . In the case of cancer progression on first-line therapy, second-line treatment options are available, with immunotherapies only recently being","cbCainbqjxUP5KQa","https://ap.wps.com/l/cbCainbqjxUP5KQa","pdf",944161,25,"English","# Introduction\n# Immunotherapy Approaches (Antibodies, Cellular Therapies, Vaccines)\n## Immune Checkpoint Inhibition\n## Patient Subgroups and Limitations\n# Summary of Clinical Trials","[{\"question\":\"Why is pancreatic cancer prognosis generally poor compared with other cancers?\",\"answer\":\"Pancreatic ductal adenocarcinoma is frequently diagnosed at late, unresectable or metastatic stages, leading to very low five-year survival. Even with advances in other solid tumors, PDAC outcomes have remained dismally poor.\"},{\"question\":\"What are the main immunomodulatory therapy approaches reviewed for pancreatic cancer?\",\"answer\":\"The review details three immunomodulation strategies: antibody-based approaches, cellular therapies, and vaccines, comparing their common targets and different shortcomings.\"},{\"question\":\"How do immune checkpoint inhibitors work in PDAC treatment, and what limitation is highlighted?\",\"answer\":\"Checkpoint pathways such as PD-1/PD-L1 prevent T-cell activation; blocking them enables immune recognition and tumor attack. Their use as second-line therapy is limited mainly to mismatch repair deficient (dMMR) tumors due to stronger responses.\"}]","Advancing Immunotherapy in Pancreatic Cancer | PDF",1790023581,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/248e1083130ffc87139bf0fec21d83a8.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29548e2ae347e124cc440caf86eb0e13.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/332a6a0fd148473e434381b6d13f8079.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e19d5b0b182405d262abdc1a02f5bfee.webp",980,1385]